Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Resverlogix ( (TSE:RVX) ) is now available.
Resverlogix Corp. has announced it will miss the March 31, 2026 deadline to file its annual audited financial statements, annual information form, and management discussion and analysis for the year ended December 31, 2025 due to delays in completing its year-end audit. The company expects to complete the audit and filings by April 10, 2026, and has applied to the Alberta Securities Commission for a management cease trade order that would restrict trading by its CEO and CFO, while allowing the public to continue trading its shares, with insiders already subject to a trading blackout and no recent material business developments disclosed.
The company and its auditor are working to finalize the required documents and Resverlogix has committed to issuing bi-weekly default status reports until the filings are made. The situation underscores near-term governance and disclosure risk for the firm, though operations appear unchanged and trading in its common shares on the Toronto Stock Exchange is expected to remain open to general investors, subject to any regulatory decision on trading orders.
More about Resverlogix
Resverlogix Corp. is a Calgary-based late-stage biotechnology company focused on epigenetics, developing first-in-class therapies aimed at regulating disease-causing gene expression. Its lead candidate, apabetalone, is being evaluated for cardiovascular disease, related comorbidities, and post-COVID-19 conditions, with the company’s shares listed on the Toronto Stock Exchange under the symbol RVX.
Average Trading Volume: 38,323
Technical Sentiment Signal: Hold
Current Market Cap: C$37.91M
For detailed information about RVX stock, go to TipRanks’ Stock Analysis page.